Marc Bourlière - Concepedia

Author

Marc Bourlière

Also Known As

B. Balkau, Bourliere Marc, Bourliere, Marc, Bourlière, M., Bourlière, Marc, Laurent Alric, M BOURLIERE, M Bourliere, M Bourlière, M. BOURLIERE

652

Publications

26K

Citations

H-Index

131

Concepts

All Affiliations

Hôpital Saint Joseph Inserm Sorbonne Université Assistance Publique – Hôpitaux de Paris Université Paris Cité

About

Marc Bourlière is an author at Hôpital Saint Joseph specializing in medicine, hepatology, and viral hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	46	100	11.3K
2	Health Sciences	8	10	1.6K
3	Public Health	7	9	1.2K
4	Engineering	2	2	121
5	Social Sciences	1	1	162

Marc Bourlière

200

Publications

21.5K

Citations

H-Index

Page 1

	Year	Citations
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection Christophe Hézode, Nicole Forestier, Geoffrey Dusheiko, New England Journal of Medicine	2009	1K
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening Vlad Ratziu, Stephen A. Harrison, Sven Francque, Gastroenterology	2016	993
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection Graham R. Foster, Nezam H. Afdhal, Stuart K. Roberts, New England Journal of Medicine	2015	845
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study Fabrice Carrat, Hélène Fontaine, Céline Dorival, The Lancet HepatologyHepatitis CViral HepatitisClinical EpidemiologyChronic Hepatitis C	2019	612
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection Marc Bourlière, Stuart C. Gordon, Steven L. Flamm, New England Journal of Medicine	2017	558
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ). Marion G. Peters, Hie‐Won Hann, Paul Martin, Gastroenterology	2003	553
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications Pierre Nahon, Valérie Bourcier, Richard Layese, Gastroenterology HepatologyHepatitis CViral HepatitisLiver PhysiologyHepatitis	2016	530
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin Stefan Zeuzem, Ira M. Jacobson, Tolga Baykal, New England Journal of Medicine	2014	514
Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C John G. McHutchison, Geoffrey Dusheiko, Mitchell L. Shiffman, New England Journal of Medicine	2007	446

Page 1